Chemotherapy-induced cognitive deficits in patients with breast cancer, predominantly in attention and verbal memory, have been observed in numerous studies. These neuropsychological findings are corroborated by the results of neuroimaging studies. The aim of this paper was to survey the reports on cerebral structural and functional alterations in women with breast cancer treated with chemotherapy (CTx). First, we discuss the host-related and disease-related mechanisms underlying cognitive impairment after CTx. We point out the direct and indirect neurotoxic effect of cytostatics, which may cause: a damage to neurons or glial cells, changes in neurotransmitter levels, deregulation of the immune system and/or cytokine release. Second, we focus on the results of neuroimaging studies on brain structure and function that revealed decreased: density of grey matter, integrity of white matter and volume of multiple brain regions, as well as their lower activation during cognitive task performance. Finally, we concentrate on compensatory mechanisms, which activate additional brain areas or neural connection to reach the premorbid cognitive efficiency.
Introduction
The results of neuropsychological examinations carried out over the last two decades indicate the occurrence of cognitive impairments in patients with breast cancer who received chemotherapy [1] . A recent metaanalysis [2] showed a decrease in capacity of attention and selective attention as well as in immediate and delayed verbal recall in patients treated with chemotherapy compared to healthy persons. Changes observed during neuropsychological testing are corroborated by the results of neuroimaging studies carried out in the recent years [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] .
The aim of this paper is to analyse the results of the neuroimaging studies conducted to date, assessing the cerebral alterations of women with breast cancer treated with chemotherapy.
The paper first focuses on the mechanisms underlying the cognitive decline, then describes the results of the studies on the structural and functional changes in the brain, and finally reports on the compensatory mechanisms observed in chemotherapy-treated women with breast cancer.
Mechanisms of chemotherapy-induced cognitive impairments
The mechanisms of cognitive impairment after chemotherapy (CTx) are still not fully understood [19, 20] . The potential role of various factors is indicated, related both to individual characteristics (host-related, soil characteristics) and the neoplastic disease itself (disease-related, seed characteristics) [21] .
Research results imply a direct neurotoxic effect of cytostatic agents, which cross the blood-brain barrier causing, for exzample damage to neurons or glial cells, changes in neurotransmitter levels [22] [23] [24] [25] [26] , and microvascular damage related to ischemia and brain damage, such as decreased vascular density in the hippocampus after the use of methotrexate [19, 27] . The indirect mechanisms are associated with the deregulation of the immune system and/or release cytokines [22, 28, 29] , hormonal changes, e.g., decreased levels of oestrogen and progesterone due to premature menopause [30, 31] , or DNA damage due to the effect of oxidative stress and accelerated telomere shortening [22, 28] . Moreover, the significance of individual factors associated with age, vascular risk factors, or the pre-cancer level of cognitive functioning and the amount of cognitive reserves, is also pointed out [31] .
The results of more recent studies indicate that some patients may exhibit genetic predisposition to cognitive impairments [20, 31] . A relationship has been shown between the allele ε4 of apolipoprotein E (APOE) gene and the deterioration of cognitive functioning in patients previously treated for breast cancer or lymphoma [26] . It was also found that persons with the catechol-O-methyltransferase (COMT)-Val genotype are more susceptible to the negative effects of CTx on cognitive functioning [32] . Genetic polymorphism may be related to the effectiveness of the blood-brain barrier (e.g. different expression of the multidrug resistance gene encoding P-glycoprotein, MDR1), the functioning of cytokines (e.g. polymorphism of the interleukin 6 cytokine gene), neurotransmitters (e.g. the polymorphism of COMT gene), and DNA repair mechanisms (e.g. the polymorphism of the X-ray repair cross complementing protein gene, XRCC1) [22, 33] .
Methods
A comprehensive literature search was conducted using the PubMed database. The following search terms and their derivatives were used: cognition, neuroimaging, fMRI, PET, MRI, chemotherapy, breast cancer. Studies had to assess brain functioning with neuroimaging methods, be published in a peer-reviewed journal, and be available as full text in English language. No time period was specified.
Results
Forty-one studies fulfilled the inclusion criteria and were selected for further analysis. Changes in the central nervous system of women with breast cancer (BC) treated with CTx were assessed in 15 studies using an MRI [6, [10] [11] [12] [13] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] and in 24 studies using functional neuroimaging methods [3, 5, 7-9, 14-18, 44-57] . In two studies both structural and functional changes were assessed [4, 58] . The characteristics of structural and functional studies in breast cancer patients are presented in Tables 1-4 .
Structural changes in the central nervous system of women with breast cancer treated with chemotherapy
In ten studies researchers used Voxel-Based Morphometry (VBM) [4, 6, 12, [37] [38] [39] [40] [41] [42] 58 ] to compare the volume of brain areas and the density of grey and white matter [59] . In five studies Diffusion-Tensor Imaging (DTI) [11, 35, 36, 38, 43] was used to measure the microstructural integrity of white matter using fractional anisotropy (FA) and structural connectivity of the brain [60] was applied. In Table 1 . Structural cerebral changes in breast cancer patients prior and after chemotherapy
Assessment
Grey matter changes White matter changes
Prior to CTx ↔ hippocampal volume in BC CTx+ and CTx- [34] ↔ density and volume of GM between BC CTx+/CTx-/HC [37, 41, 58] ↔ GM volume in DLPFC and superior parietal cortex between BC CTx+/CTx-/HC [58] ↓ left cingulate GM density in BC CTx-compared to HC [12] ↓ WM volume in frontal, parietal and limbic regions depending on type of analyses and covariates entered [41] ↓ WM integrity in BC compared to HC [58] 1-12 months after CTx ↓ prefrontal, parahippocampal, cingulate gyrus, precuneus volume [6] ↓ bilateral frontal, temporal (including hippocampus and adjacent medial temporal structures) and cerebellar regions and right thalamus GM density in BC CTx+ than HC [37] ↓ left frontal CH density in BC CTx+ compared to HC [12] ↓ frontal, temporal, parietal, and occipital volume [42] ↓ FA in frontal, parietal and occipital tracts after CTx+ [11, 36] ↓ prefrontal, parahippocampal, cingulate gyrus, precuneus volume [6] 1-2 years after CTx ↓↑ bilateral superior frontal, left middle frontal, right superior temporal and cerebellar GM density [37] ↓ persisted in bilateral cerebellum, right thalamus and medial temporal lobe, left middle gyrus and right precentral, medial frontal and superior frontal gyri [37] ↓ in bilateral frontal and temporal regions [42] ↓ global hippocampal volume in 8% of BCS CTx+ [10] ↓ posterior hippocampus in 11% BCS CTx+ compared to HC [10] ↓ FA in genu of corpus callosum in BCS CTx+ than HC [35] 2-10 years after CTx one study semi-automatic segmentation procedure was used [34] and in three automatic seqmentation procedure were used [10, 13, 39] . Most of the studies were conducted in cross-sectional design: 10 in breast cancer survivors treated with CTx [4, 6, 10, 13, 34, 35, [38] [39] [40] 43 ] and 2 in breast cancer patients prior to CTx [41, 58] ; 5 studies were conducted with longitudinal design [11, 36, 37, 61, 62] . The results obtained from breast cancer patients treated with CTx were compared to breast cancer patient without CTx [34, 38, 55] , healthy controls [4, 10, 13, 35, 40, 41, 62] , non-cancer reference subjects [39, 43] , or breast cancer patients without CTx and healthy controls [6, 36, 37, 58, 61] . In four studies breast cancer patients were treated with the same schema of CTx [38, 39, 43, 58] and in the other studies different schemas were applied [4, 6, 10-13, 34-37, 40, 42] . A summary of the structural cerebral changes described in analyzed studies is presented in Table 1 .
The evaluation of the anatomical properties of the brain using MRI yields information on the structural changes occurring over time and makes it possible to discern the differences between groups. As already mentioned in the discussion of some of the studies, supplementing the research using MRI with functional imaging techniques is a method to obtain fuller descriptions of chemotherapyrelated cognitive impairment (CRCI) [63] .
Functional changes in the central nervous system of women with breast cancer treated with chemotherapy
The functional studies were carried out using fMRI [4, 5, 7, 8, 14-16, 18, 48-55, 57, 58, 64] , EEG [44, 45, 65] , resting state fMRI [3, 17] , PET [9] and Pulsed Arterial Spin Labelling MRI Perfusion [56] . During fMRI cognitive processes were assessed using verbal and visual working memo- Table 2 . Functional changes in breast cancer patients prior to and after chemotherapy
Functional changes
Prior to CTx ↑ bifrontal and biparietal regions in high load task in BC compared to HC [48] ↑ inferior frontal gyrus, insula, thalamus and midbrain during working memory in BC [49] ↑ bifrontal and ↓ left parietal in BC CTx+/CTx-compared to HC [8] ↓ cerebellar in BC than NCN [50] ↑ prefrontal with increasing task difficulty on a planning task compared to HC, but not during a memory task [58] ≠ neural response -↑ spatial variance in executive network activity [54] ↔ in the multitasking network [55] ↔ perfusion in GM between BC CTx+/CTx- [56] 1-12 months after CTx
↓ in left inferior frontal when comparing to prior CTx+ [8] ↑ in left thalamic and posterior middle temporal gyrus compared with HC and ↑ in right cerebellar and left inferior precentral and posterior middle temporal gyrus compared with the CTx- [8] ↓ bilateral insula, left inferior orbitofrontal cortex and left middle temporal gyrus [15] ↑ brain activity magnitude in BC CTx+ with CIA [52] ↓ functional connectivity [53] ↓ in the multitasking network [55] ↓ in frontospatial executive network and cognitive complaints [18] ↑ perfusion in superior and posterior regions in BC CTx+ not related with ↓ frontal GM density, however ↓ frontal GM density was associate with ↓ perfusion in bilateral frontal and parietal lobes [56] ≠ resting state functional connectivity in BCS women with subjective cognitive complaints [17] 1-2 years after CTx ↑ in bifrontal and biparietal regions during cognitive task but not significant differences in test performance [46] ↓↑ in left frontal region as prior to CTx; ↓ persisted in middle frontal gyrus [8] ↑ partial return to baseline in the dorsal attention network [53] 2-10 years after CTx ↓ earlier P3 component in BCS CTx+ [44, 65] ↓ amplitude of P3 component in BCS H CTx+ [45, 65] ≠ cerebral blood flow in frontal cortex and cerebellum during memory task in BCS CTx+ [9] ↓ left middle dorsolateral prefrontal cortex and premotor cortex in BCS CTx+ compared to HC, ↓ left caudal prefrontal cortex and worse test performance in BCS CTx+ compared to CTx-and HC [7] ↓ prefrontal and parietal areas in BCS CTx+ compared to CTx-; ↑ frontal activation -better test performance [5] ≠ global brain network organisation: ↑ global clustering, ≠ regional network characteristics in frontal, striatal and temporal areas [3] ↓ left precuneus connectivity in AC CTx+ and ↓ verbal performance [16] ≠ default mode network resting-state functional connectivity [51] ↓ prefrontal cortex during encoding task [14] ↑ in right superior temporal gyrus extending into bilateral fusiform, bilateral lingual gyri, left hippocampus, bilateral basal ganglia, right precentral gyrus, right superior and inferior frontal gyri, right middle frontal gyrus, bilateral inferior frontal gyrus, right cingulate gyrus, bilateral insula, bilateral parahippocampal gyrus, bilateral cuneus, bilateral precuneus, bilateral superior parietal lobe, and cerebellum during recall task [14] > 10 years after CTx ↓ prefrontal and parietal areas [57] ↔ no changes/no differences in activation; ↓ decreased activation; ↑ increased activation; ≠ altered activation; [49, 50] or with breast cancer patients without CTx and healthy controls [7-9, 18, 51, 54-56] . In three studies breast cancer patients were treated with the same schema of CTx [44, 45, 65] , and in the others studies different schemas were applied [3, 4, 7, 8, 14-18, 45-48, 50-57] . Summary of functional changes described in the analysed studies (Table 2) .
↓↑ recovery CTx+ cancer patients treated with standard dose of chemotherapy; HCTx+ -cancer patients treated with high-dose chemotherapy; CTx--cancer patients without chemotherapy; BC -breast cancer patients; BCS -breast cancer survivors; HC -healthy controls; NCN -non-cancer controls; CIA -chemotherapy-induced amenorrhoea

Compensatory mechanisms
An interesting study to observe the mechanism underlying the process of coping with cognitive demand was performed on 60-year-old homozygous twin sisters [46] . One of the sisters was previously (22 months earlier) treated for breast cancer that AC+T adjuvant chemotherapy (four cycles of AC followed by four cycles of T -docetaxel), and received hormonal therapy (tamoxifen) during the study. While diseases and therapies which could negatively affect cognitive functioning were excluded in both sisters, they were found to have the allele ε4 of apolipoprotein E, associated with the occurrence of cognitive deficits [26] . Cognitive functioning was evaluated using standard neuropsychological tests, a self-assessment questionnaire, and functional magnetic resonance imaging (fMRI). It was found that the twin treated with CTx reported much greater problems with cognitive functioning. Nevertheless, the results of the performed neuropsychological tests lay within the norm and differed minimally from those of the healthy sister. The fMRI results showed white matter hyperintensities in both sisters, which are also observed among the carriers of the allele ε4 of apolipoprotein E [66, 67] . No coherent pattern of the differences in the volumes of selected brain areas (including the hippocampus, amygdala, frontal part of the hippocampal gyrus cortex, and corpus callosum) were found between sisters. Nonetheless, interesting results were obtained in an fMRI examination during the performance of a task evaluating working Kesler et memory using the n-back paradigm. It was shown that the more the task was taxing to the working memory, the greater was the scope of activation of brain areas (bilateral stimulation of frontal and parietal areas) in the sister treated with CTx compared to the healthy one. However, no significant differences in the task performance level were observed [64] .
CTx+ -cancer patients treated with standard dose of chemotherapy; HCTx+ -cancer patients treated with high-dose chemotherapy; CTx--cancer patients without chemotherapy; BC -breast cancer patients; BCS -breast cancer survivors; HC -healthy controls; SRCI -self-reported cognitive impairment; A -mean ± SD age; TSCTx -mean ± SD age time since chemotherapy; DTI -diffusion tensor imaging; MRI -magnetic resonance imaging; FA -fractional anisotropy; VBM voxel based morphometry; ASP -automatic segmentation procedure; ROI -region of interes; GR -gray matter; WM -white matter; CS -cross-sectional; L -longitudinal; T -time point; S -sample
The obtained results indicate that in order to enable the adequate performance level of a task by the twin treated with CTx, it was necessary to activate a greater area of neural networks, which most likely requires greater mental effort, reflected in the greater number of complaints about cognitive functioning [64, 68] . It may be supposed that, if the task were made increasingly more taxing, at a certain level of difficulty the compensation for the deficits would be insufficient and the test results would become poorer [68] . The activation of larger areas of the brain in order to maintain the appropriate performance level in cognitive tasks was also confirmed by numerous studies on people aging normally [69] [70] [71] .
The activation of compensatory mechanisms was also confirmed in a more recent longitudinal study carried out by McDonald, Conroy, Ahles, West, and Saykin [8] , which assessed working memory using the n-back paradigm and brain activation using fMRI in women with breast cancer and in healthy ones. The measurements were taken three times: before chemotherapy, and one month, and one year after treatment. The performance level of n-back tasks did not differ significantly between groups; however, changes in activation patterns were observed in all three measurements, both during greater and lesser working memory-loaded tasks. Moreover, greater activation of prefrontal areas was found in the examinations before and one year after the treatment.
Thanks to compensatory neuroplasticity, the cognitive functioning of people treated with chemotherapy can be maintained on an unchanged or only slightly deteriorated level compared to their premorbid abilities. The studies on the levels of brain activation carried out with fMRI revealed that additional brain areas become involved in the performance of lower difficulty tasks, allowing their performance to remain within the norm. A deterioration in functioning becomes visible when the increasing difficulty exceeds the efficiency of compensatory mechanisms [68] .
Conclusions
Based on the studies carried out using neuroimaging methods, it is possible to describe the cognitive deficits caused by adjuvant chemotherapy [72] . Specific, albeit small, structural changes and functional changes within the central nervous system are associated with the minor specific impairments of cognitive functions described in literature [72] .
The changes in the activity of various cerebral regions in patients treated with chemotherapy indicate that the brain functions in an altered way, by activating new areas or creating new neural connections to reach the same cognitive efficiency. A greater expenditure of energy on mental activities can lead to increased fatigue and be associated with the deterioration in cognitive effectiveness and quality of life suffered by the patients [63] . Even though neuroimaging methods are not free from limitations, using them in CRCI studies in combination with self-descriptive and neuropsychological methods may yield a broader image of the described phenomenon [72] .
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